3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
84
Breast Neoplasms
10
Neoplasm Metastasis
7
Neoplasms
5
Prostatic Neoplasms, Castration-Resistant
4
Prostate Cancer Metastatic
4
Metastatic Castration-Resistant Prostate Cancer
4
Metastatic Castration-resistant Prostate Cancer
3
Castration-resistant Prostate Cancer
3
Triple Negative Breast Neoplasms
2
Castration Resistant Metastatic Prostate Cancer
2
Adenocarcinoma of the Prostate
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Prostatic Diseases
1
Prostate Carcinoma Metastatic to the Bone
1
Prostate Adenocarcinoma
1
Primary Breast Cancer ER+ve
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoadjuvant Therapy
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Metastatic Hormone-sensitive Prostate Cancer
1
Interventions
padeliporfin
2
talazoparib
1
sipuleucel-T
1
luprolide acetate gel depot
1
ixabepilone
1
enzalutamide
1
Therapeutics
1
Pluvicto
1
Paclitaxel
1
Nivolumab
1
Leuprolide
1
Ipilimumab
1
Imatinib Mesylate
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Prostatic Diseases
×
enzalutamide
×
Clear all
NCT06582628
2024-12-02
TEAM PC
Fundacion Oncosur
Phase 2
Recruiting
78 enrolled